S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
The Day of Financial Reckoning Is Near (Ad)
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Italy's Lake Garda shrinks to near-historic low amid drought
The Financial Day of Reckoning Has Begun (Ad)
Germans urged to cap heat in offices this winter to save gas
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
The Financial Day of Reckoning Has Begun (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
The Day of Financial Reckoning Is Near (Ad)
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Italy's Lake Garda shrinks to near-historic low amid drought
The Financial Day of Reckoning Has Begun (Ad)
Germans urged to cap heat in offices this winter to save gas
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
The Financial Day of Reckoning Has Begun (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
The Day of Financial Reckoning Is Near (Ad)
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Italy's Lake Garda shrinks to near-historic low amid drought
The Financial Day of Reckoning Has Begun (Ad)
Germans urged to cap heat in offices this winter to save gas
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
The Financial Day of Reckoning Has Begun (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
The Day of Financial Reckoning Is Near (Ad)
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Italy's Lake Garda shrinks to near-historic low amid drought
The Financial Day of Reckoning Has Begun (Ad)
Germans urged to cap heat in offices this winter to save gas
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
The Financial Day of Reckoning Has Begun (Ad)
NASDAQ:XNCR

Xencor - XNCR Stock Forecast, Price & News

$30.47
+1.81 (+6.32%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$28.87
$30.75
50-Day Range
$19.74
$32.44
52-Week Range
$19.35
$43.61
Volume
279,423 shs
Average Volume
293,716 shs
Market Capitalization
$1.82 billion
P/E Ratio
89.62
Dividend Yield
N/A
Price Target
$51.83

Xencor MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
70.1% Upside
$51.83 Price Target
Short Interest
Bearish
5.33% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.24
Upright™ Environmental Score
News Sentiment
-0.08mentions of Xencor in the last 14 days
Based on 10 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.74) to ($2.47) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.17 out of 5 stars

Medical Sector

577th out of 1,135 stocks

Pharmaceutical Preparations Industry

293rd out of 557 stocks

XNCR stock logo

About Xencor (NASDAQ:XNCR) Stock

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. Its product candidates include Plamotamab, a tumor-targeted antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab that is in Phase II clinical trial to treat neuroendocrine tumors. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104 and XmAb841, which are in Phase I clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase I clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; and Novartis XmAb. In addition, it is developing VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; VIR-2482 that is in Phase 1/2 clinical trial to trat influenza A; VIR-7832, which is in Phase 1b/2a trial to treat mild-to-moderate COVID-19; and BMS-986414 + BMS-986413 is in Phase 2/3 NIH ACTIV-2 trial in treating COVID-19. Further, the company is developing AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, mild cognitive impairment, and depression. Xencor, Inc. was incorporated in 1997 and is headquartered in Monrovia, California.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on XNCR shares. StockNews.com cut Xencor from a "hold" rating to a "sell" rating in a research report on Thursday, August 4th. Piper Sandler lowered their price target on Xencor from $66.00 to $42.00 and set an "overweight" rating on the stock in a research report on Monday, May 23rd. Finally, Canaccord Genuity Group reaffirmed a "buy" rating and issued a $50.00 target price on shares of Xencor in a report on Wednesday, July 6th. One analyst has rated the stock with a sell rating and eight have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $51.83.

Xencor Price Performance

Shares of XNCR traded up $1.81 on Friday, reaching $30.47. 279,423 shares of the stock traded hands, compared to its average volume of 293,716. The firm has a market cap of $1.82 billion, a price-to-earnings ratio of 89.62 and a beta of 0.61. Xencor has a 12 month low of $19.35 and a 12 month high of $43.61. The stock's 50-day moving average price is $27.51 and its 200-day moving average price is $27.77.

Receive XNCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xencor and its competitors with MarketBeat's FREE daily newsletter.

XNCR Stock News Headlines

Xencor (XNCR) Investor Presentation - Slideshow
Xencor (NASDAQ:XNCR) Cut to Sell at StockNews.com
Xencor Reports Second Quarter 2022 Financial Results
Brokerages Set Xencor, Inc. (NASDAQ:XNCR) PT at $52.00
Xencor (NASDAQ:XNCR), Short Interest Report
See More Headlines
Receive XNCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xencor and its competitors with MarketBeat's FREE daily newsletter.

XNCR Company Calendar

Last Earnings
11/08/2021
Today
8/14/2022
Next Earnings (Estimated)
11/14/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:XNCR
Employees
254
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$51.83
High Stock Price Forecast
$60.00
Low Stock Price Forecast
$42.00
Forecasted Upside/Downside
+70.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
8 Analysts

Profitability

Net Income
$82.63 million
Pretax Margin
7.77%

Debt

Sales & Book Value

Annual Sales
$275.11 million
Cash Flow
$1.71 per share
Book Value
$12.44 per share

Miscellaneous

Free Float
57,173,000
Market Cap
$1.82 billion
Optionable
Optionable
Beta
0.61

Key Executives

  • Dr. Bassil I. Dahiyat Ph.D. (Age 52)
    Co-Founder, CEO, Pres & Director
    Comp: $1.08M
  • Mr. John J. Kuch (Age 63)
    Sr. VP & CFO
    Comp: $648.03k
  • Dr. John R. Desjarlais (Age 58)
    Sr. VP of Research & Chief Scientific Officer
    Comp: $725.03k
  • Ms. Celia E. Eckert J.D. (Age 49)
    Sr. VP, Gen. Counsel & Corp. Sec.
    Comp: $600.93k
  • Dr. Allen S. Yang M.D. (Age 54)
    Ph.D., Sr. VP & Chief Medical Officer
    Comp: $748.13k
  • Mr. Charles Liles
    Associate Director and Head of Corp. Communications & Investor Relations
  • Ms. Jennifer Sandoz
    VP of HR
  • Dr. Jeremy Grunstein Ph.D.
    Sr. VP of Bus. Devel.
  • Mr. Kirk Rosemark RAC (Age 57)
    Sr. VP of Regulatory Affairs & Quality Assurance













XNCR Stock - Frequently Asked Questions

Should I buy or sell Xencor stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Xencor in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" XNCR shares.
View XNCR analyst ratings
or view top-rated stocks.

What is Xencor's stock price forecast for 2022?

8 brokers have issued 1 year target prices for Xencor's stock. Their XNCR share price forecasts range from $42.00 to $60.00. On average, they predict the company's stock price to reach $51.83 in the next twelve months. This suggests a possible upside of 70.1% from the stock's current price.
View analysts price targets for XNCR
or view top-rated stocks among Wall Street analysts.

How have XNCR shares performed in 2022?

Xencor's stock was trading at $40.12 at the beginning of the year. Since then, XNCR stock has decreased by 24.1% and is now trading at $30.47.
View the best growth stocks for 2022 here
.

When is Xencor's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our XNCR earnings forecast
.

How were Xencor's earnings last quarter?

Xencor, Inc. (NASDAQ:XNCR) announced its quarterly earnings data on Monday, November, 8th. The biopharmaceutical company reported ($0.69) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.06. The biopharmaceutical company earned $19.68 million during the quarter, compared to analysts' expectations of $17.63 million. Xencor had a trailing twelve-month return on equity of 3.15% and a net margin of 7.77%. During the same period last year, the company posted ($0.22) earnings per share.

What is Bassil I. Dahiyat's approval rating as Xencor's CEO?

6 employees have rated Xencor Chief Executive Officer Bassil I. Dahiyat on Glassdoor.com. Bassil I. Dahiyat has an approval rating of 81% among the company's employees.

What other stocks do shareholders of Xencor own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Xencor investors own include Intelsat (I), Bank of America (BAC), Apollo Global Management (APO), Cypress Semiconductor (CY), NVIDIA (NVDA), AbbVie (ABBV), Exelixis (EXEL), Intel (INTC), AMC Entertainment (AMC) and Ciena (CIEN).

What is Xencor's stock symbol?

Xencor trades on the NASDAQ under the ticker symbol "XNCR."

Who are Xencor's major shareholders?

Xencor's stock is owned by many different retail and institutional investors. Top institutional shareholders include FMR LLC (9.02%), Primecap Management Co. CA (8.03%), Loomis Sayles & Co. L P (3.04%), Candriam S.C.A. (1.53%), Northern Trust Corp (1.16%) and JPMorgan Chase & Co. (0.85%). Insiders that own company stock include Allen Yang, Bassil I Dahiyat, Bassil I Dahiyat, Celia Eckert, John J Kuch, John R Desjarlais, John S Stafford III and Ronin Capital, Llc.
View institutional ownership trends
.

How do I buy shares of Xencor?

Shares of XNCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Xencor's stock price today?

One share of XNCR stock can currently be purchased for approximately $30.47.

How much money does Xencor make?

Xencor (NASDAQ:XNCR) has a market capitalization of $1.82 billion and generates $275.11 million in revenue each year. The biopharmaceutical company earns $82.63 million in net income (profit) each year or $0.34 on an earnings per share basis.

How many employees does Xencor have?

The company employs 254 workers across the globe.

How can I contact Xencor?

Xencor's mailing address is 111 WEST LEMON AVENUE, MONROVIA CA, 91016. The official website for the company is www.xencor.com. The biopharmaceutical company can be reached via phone at (626) 305-5900, via email at investors@xencor.com, or via fax at 626-305-0350.

This page (NASDAQ:XNCR) was last updated on 8/14/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.